bluebird bio, Inc. (BLUE)
NASDAQ: BLUE · Real-Time Price · USD
4.080
+0.290 (7.65%)
At close: Mar 28, 2025, 4:00 PM
4.450
+0.370 (9.07%)
After-hours: Mar 28, 2025, 7:59 PM EDT

Company Description

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States.

The company’s product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.

Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with β-thalassemia.

The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010.

bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

bluebird bio, Inc.
bluebird bio logo
Country United States
Founded 1992
IPO Date Jun 19, 2013
Industry Biotechnology
Sector Healthcare
Employees 375
CEO Andrew Obenshain

Contact Details

Address:
455 Grand Union Boulevard
Somerville, Massachusetts 02145
United States
Phone 339 499 9300
Website bluebirdbio.com

Stock Details

Ticker Symbol BLUE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001293971
CUSIP Number 09609G100
ISIN Number US09609G1004
SIC Code 2836

Key Executives

Name Position
Andrew Obenshain President, Chief Executive Officer and Director
Thomas J. Klima Chief Commercial Officer and Chief Operating Officer
Dr. Richard A. Colvin M.D., Ph.D. Chief Medical Officer
Oliver James Sterling III Chief Financial Officer and Principal Accounting Officer
Joseph D. Vittiglio Esq., J.D. Chief Legal and Business Officer and Secretary
Andrea Walton Chief People Officer
Kasra Kasraian Senior Vice President of Quality, Regulatory and CMC Sciences
Scott Shoemaker Senior Vice President of Technical Operations

Latest SEC Filings

Date Type Title
Mar 28, 2025 SC 14D9/A Filing
Mar 28, 2025 8-K Current Report
Mar 27, 2025 10-K Annual Report
Mar 25, 2025 SC TO-T/A Filing
Mar 21, 2025 SC TO-T/A Filing
Mar 7, 2025 SC 14D9 Filing
Mar 7, 2025 SC TO-T Filing
Mar 3, 2025 144 Filing
Mar 3, 2025 144 Filing
Mar 3, 2025 144 Filing